[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rachel Yehuda\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100600829","phase-1-mdma-assisted-therapy-for-mental-healthcare-providers-100600829",false,"NCT07102576","MDMA-Assisted Therapy for Mental Healthcare Providers","A Phase 1, Open-Label Study to Assess Psychological and Biological Effects of MDMA Assisted Therapy When Administered to Mental Health Providers in Training to be MDMA-Assisted Therapists","Inclusion Criteria:\n\n* Are at least 18 years at the time of signing the informed consent.\n* Fluent in English\n* Able to swallow pills\n* Agree to have study visits audiovisually recorded\n* Able to provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of the participant becoming unwell or unreachable.\n* Must be licensed, license-eligible, or trainees in a relevant healthcare\u002Fmental health profession\n* Must be learning or have been certified to conduct MDMA-assisted therapy through the Lykos MDMA-Assisted Therapy Training program or authorized affiliate program\n* Body weight of at least 45 kilograms (kg; or 100 pounds (lbs)).\n\nExclusion Criteria\n\n* Have engaged in a new form of psychiatric or mental health care within 12 weeks of enrollment\n* Have a current alcohol or cannabis use disorder of any severity within the 12 months prior to enrollment\n* Have a substance use disorder of any severity within 12 months prior to enrollment\n* Any suicidal ideation within the last 6 months\n* Repetitive or recent use of Ecstasy\u002FMDMA\n* Current enrollment in any other clinical study involving an investigational study treatment or any other type of medical research, unless approved by the study clinician\n* Meet diagnostic criteria for a Major Depressive Episode currently or within the prior 3 months or meet diagnostic criteria for a current anxiety disorder assessed\n* Have a current eating disorder with compensatory behaviors\n* Have a history of, or a current primary psychotic disorder or bipolar disorder\n* Previous participation in a clinical trial that included administration of MDMA\n* Individuals in a personal relationship with the site investigator\n* Are pregnant or nursing or are able to become pregnant and are not practicing an effective means of contraception",true,"ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a phase 1, open-label study to assess changes in mental well-being following MDMA administration within a therapeutic setting, in mental health providers who are in training to become MDMA assisted therapists. Secondary outcome measures will examine the effects on provider burnout, provider self-efficacy, mood, self-compassion, quality of life, and other psychological factors. Participants will work with a co-therapy pair as they engage in a preparatory session, one experimental session with MDMA, and an integration session the following day.",[27],"Mental Wellbeing",[29,30,31,32,33],"Psychedelic Therapy","MDMA","MDMA-Assisted Therapy","Mental Health","Therapist","RECRUITING","2026-03-26",{"date":37,"type":38},"2026-03-27","ACTUAL",{"date":40,"type":38},"2026-02-11",{"date":42,"type":21},"2029-12-21",{"name":44,"class":45},"Rachel Yehuda","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100585192","phase-2-psilocybin-assisted-therapy-for-intergenerational-trauma-100585192","NCT06899165","Psilocybin-Assisted Therapy for Intergenerational Trauma","Processing Intergenerational Trauma With Psilocybin-Assisted Therapy","Inclusion criteria:\n\n* Age at least 18 years old at time of signing the informed consent\n* Biological child of at least one parent who directly survived\u002Fescaped a genocide\n* Meets diagnostic criteria for a depressive or anxiety disorder\n* Capable of providing informed consent and complying with study procedures\n* Currently using or agreeing to use adequate contraceptive methods.\n* Fluent in speaking and reading English\n* Able to swallow pills\n* Agrees to have study visits recorded with audio and video\n* Able to provide a contact person who can be reached by investigators in the event of the participant becoming unwell or unreachable\n* Agrees to inform the investigators within 48 hours of any medical conditions and procedures\n* Agrees to release of outside medical and psychiatric records\n* Must not participate in any other interventional clinical trials for the duration of the study.\n* Must commit to medication dosing, therapy, and all study procedures.\n\nExclusion Criteria:\n\n* Not able to give adequate informed consent.\n* Was directly exposed to or survived a genocide.\n* Has a history of any medical condition, or any significant clinical finding on screening tests, that could make receiving psilocybin harmful.\n* Has acute, severe or unstable medical illness.\n* Has a history of stroke or Transient Ischemic Attack (TIA).\n* Has a history of psychiatric hospitalization within the last 6 months.\n* Current serious suicide risk.\n* Unable or unwilling to safely taper off prohibited psychiatric medications.\n* Abusing alcohol or other substances.\n* Has used psychedelics within 3 months of enrollment.\n* Are pregnant or nursing or able to become pregnant and are not practicing an effective means of contraception.",{"count":55,"type":21},100,[57],"PHASE2","This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders.\n\nThe study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.",[60,61,62],"Psychological Stress","Depression","Anxiety",[64,65,66,67,68,69],"psilocybin","psilocybin-assisted therapy","intergenerational trauma","psychedelic","stress","genocide","2025-09-02",{"date":72,"type":38},"2025-09-08",{"date":74,"type":38},"2025-08-28",{"date":76,"type":21},"2030-01-02",{"name":44,"class":45},""]